Chronic Kidney Disease When There’s No “Quick Fix” for What Ails You – Interview  

Chronic Kidney Disease When There’s No “Quick Fix” for What Ails You – Interview   

Living with a chronic disease is complicated. Even more so, for the 37 million Americans living with chronic kidney disease (CKD), they may feel stuck, depressed, and suffer economic pressure.

According to a recent report,

more than half of patients living with CKD said that the complications of their disease caused a profound impact on their day-to-day activities and overall quality of life.[i] This includes impact on their mental well-being, sleep schedule, and meal management.

One of the complications that patients most commonly experience with CKD is anemia, which, if left untreated, can become life-threatening.

Anemia is a common yet serious medical condition

in which patients have fewer red blood cells (RBCs) than normal and low levels of hemoglobin, a protein in RBCs that carries oxygen throughout the body. This causes the body to work harder to deliver oxygen to the tissues and organs and often results in extreme fatigue, weakness, and dizziness.

Anemia of CKD is often underdiagnosed and undertreated.

Stagnation in science has led to a 30-year dearth in new treatments for anemia of CKD, and reported treatment rates for anemia of CKD are typically low at around 10-15%.[ii] Patients often feel overwhelmed and uncertain about what’s happening to their bodies, making it hard to get the help they need. As their condition progresses, many patients end up accepting their exhaustion and lower quality of life as the “new normal” and stop expecting anything different.

After decades of inertia, recent advances have expanded the understanding of the complex pathophysiology of anemia of CKD.

Join me in a recent interview

with Dr. Robert Provenzano, an Associate Clinical Professor of Medicine at Wayne State University School of Medicine in Detroit Michigan, as he discussed anemia of CKD, its symptoms, and why it’s important to seek treatment. Dr. Provenzano also outlined some of the recent scientific developments that are leading to a shifting treatment paradigm for patients who live with anemia of CKD, so they can get more out of life.

See the entire interview here:

For more information, go to

BIO: Dr. Robert Provenzano

Robert Provenzano is an Associate Clinical Professor of Medicine at Wayne State University School of Medicine in Detroit Michigan.

He has served previously as the Chief of the Division of Nephrology, Hypertension & Transplantation, Director of Nephrology Research, and Director of Acute Dialysis Services at St. John Hospital & Medical Center in Detroit, MI., Chief Operating Officer of St. Clair Specialty Physicians in Detroit, and the Vice President of Medical Affairs for DaVita Inc. Dr. Provenzano has recently overseen all of the owned & managed practice for DaVita as its CMO for Nephrology Practice Solutions (NPS). Currently, he has focused, in a consultant role, on anemia management for CKD and ESRD patients for several Pharmaceutical organizations.

Dr. Provenzano completed his internship and residency at St. John Hospital and Medical Center. His nephrology fellowship was completed at Henry Ford Hospital in Detroit, MI.

Interview courtesy of AstraZeneca

[i] AstraZeneca Internal. Chronic Kidney Disease Personal Impact Index (CKD PII). Page 2.

[ii] Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.doi:10.1371/journal.pone.0084943

Cynthia Tait

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: